Magnolol (Biphenyl Neolignan · Anti-inflammatory · Oral Health)

Compound	Magnolol
Chemical class	Polyphenol — Biphenyl Neolignan (Honokiol Isomer)
CAS	528-43-8
Primary source	Magnolia officinalis (houpu magnolia bark)
Key applications	Anti-inflammatory, anxiolytic, antimicrobial, anti-adipogenic
Claim strength	Moderate
Typical form	Magnolia bark extract standardised to magnolol + honokiol; magnolol 50% isolate
Buy from Herbuno	Magnolol 50% Powder (Magnolia Bark Extract) | Standardized Magnolia officinalis → Honokiol 50% Powder (Magnolia Bark Extract) | Standardized Magnolia officinalis →

Name origin: From Magnolia + -ol — the primary neolignan of magnolia bark alongside its isomer honokiol. Magnolol and honokiol share an identical molecular formula (C18H18O2) and both are 5,5′-diallyl-2,2′-biphenol isomers; they differ only in the position of one allyl group relative to the two phenol hydroxyls. Traditional use: Identical to honokiol — both are primary actives in Hou Po (magnolia bark) in TCM and Kampo, used for digestive disorders, anxiety, muscle spasm, and respiratory complaints for over two millennia. They are always co-present and are not separated in traditional preparations. Research trajectory: Magnolol has its own distinct research profile beyond shared mechanisms with honokiol, including PPAR-γ activation (relevant to adipogenesis and metabolic syndrome), stronger anti-inflammatory activity in some assay systems, and antimicrobial activity against oral pathogens relevant to dental health. Commercial source: Magnolol is commercially available as a high-purity standardised extract (50% HPLC) from Magnolia officinalis bark. See sourcing options below.

---

Evidence for Magnolol Applications

Anti-inflammatory: Magnolol inhibits NF-κB, COX-2, and 5-LOX — the same dual pathway coverage as honokiol. In comparative assay systems, magnolol demonstrates stronger COX inhibition than honokiol in some models. In vivo anti-inflammatory efficacy in carrageenan paw oedema, arthritis, and TNBS colitis models is well-documented. Claim strength: Moderate.

PPAR-γ activation and metabolic: Magnolol activates PPAR-γ in adipocyte models, which has paradoxically both pro-differentiation (at low concentrations) and anti-adipogenic (via insulin sensitisation pathway modulation) effects depending on context and dose. In diabetic animal models, magnolol improves insulin sensitivity and reduces fasting blood glucose. Claim strength: Moderate.

Antimicrobial and oral health: Magnolol has potent antimicrobial activity against oral pathogens (Streptococcus mutans, Porphyromonas gingivalis) at low micromolar concentrations, with anti-biofilm activity relevant to dental caries and periodontitis prevention. This application has attracted commercial interest in oral health product development. Claim strength: Moderate.

---

Dosage & Formulator Specification

Human clinical data from combined magnolia bark extract (honokiol + magnolol): 200–400 mg/day total extract for stress and metabolic applications, delivering approximately 50–100 mg combined honokiol + magnolol. For isolated magnolol at Herbuno’s 50% purity: 50–100 mg/day magnolol is a working formulation range for anti-inflammatory and metabolic applications.

For oral health applications, magnolol at 0.01–0.1% in chewing gum, mouthwash, or lozenge formats delivers antimicrobial concentrations to the oral cavity. Some commercial oral health products (toothpaste, mouthwash) include standardised magnolia bark extract at concentrations effective for S. mutans inhibition.

Magnolol has similar physicochemical properties to honokiol (logP ~3.9, low aqueous solubility). Lipid-based delivery is preferred for oral bioavailability. Stable under standard manufacturing conditions. Same pregnancy contraindication as honokiol applies.

---

Frequently Asked Questions — Magnolol

Should a formulator choose honokiol or magnolol for a specific application?
For anxiolytic and neuroprotective applications — honokiol has stronger evidence and CNS penetration data. For anti-inflammatory and metabolic applications — magnolol has slightly stronger COX inhibition and PPAR-γ data. For oral health — magnolol has superior oral pathogen antimicrobial evidence. In practice, a combined magnolia bark extract delivering both at their natural ratio provides the broadest activity coverage and aligns with the clinical evidence base, which is primarily from extract combinations rather than isolated compounds.

Can magnolol be used in a dental/oral health formulation?
Yes — magnolol’s antimicrobial activity against S. mutans (primary caries pathogen) and P. gingivalis (primary periodontitis pathogen) at low concentrations supports its inclusion in functional oral health products. Inclusion at 0.01–0.05% in mouthwash or toothpaste is consistent with antimicrobial in vitro data. Regulatory classification as a cosmetic versus pharmaceutical product must be considered depending on specific claims made.

Is there any clinical evidence specifically for magnolol versus combined honokiol + magnolol?
Most human clinical evidence for magnolia bark preparations uses combined honokiol + magnolol extracts rather than isolated magnolol. Clinical attribution specifically to magnolol requires either isolated magnolol studies or mechanistic work clarifying which compound drives specific outcomes. Currently, the most defensible clinical claims reference the combined extract evidence base.

Does magnolol activate PPAR-γ like thiazolidinedione drugs?
Magnolol has PPAR-γ agonist activity in cell models, overlapping mechanistically with the thiazolidinedione (TZD) drug class (rosiglitazone, pioglitazone). However, its PPAR-γ affinity and selectivity are substantially lower than pharmaceutical TZDs. The insulin-sensitising effects observed in animal diabetic models suggest meaningful PPAR-γ engagement in vivo, but clinical translation to TZD-equivalent glucose control in humans is not established. Magnolol should not be positioned as a natural alternative to TZD medications.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery